Acurx Pharmaceuticals, Inc. (ACXP)

NASDAQ: ACXP · Delayed Price · USD
3.64
-0.70 (-16.13%)
At close: Jan 21, 2022 4:00 PM
3.99
0.35 (9.62%)
After-hours:Jan 21, 2022 5:45 PM EST
Market Cap37.19M
Revenue (ttm)n/a
Net Income (ttm)-11.21M
Shares Out10.22M
EPS (ttm)-1.48
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume359,525
Open4.23
Previous Close4.34
Day's Range3.15 - 4.37
52-Week Range3.20 - 8.74
Betan/a
AnalystsBuy
Price Target12.00 (+229.7%)
Earnings Daten/a

About ACXP

Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and ...

IndustryBiotechnology
IPO DateJun 25, 2021
Employees2
Stock ExchangeNASDAQ
Ticker SymbolACXP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for ACXP stock is "Buy" and the 12-month stock price forecast is 12.00.

Price Target
$12.00
(229.67% upside)
Analyst Consensus: Buy

News

Acurx Announces First Patient Enrolled in Phase 2b Clinical Trial of its Lead Antibiotic for Treatment of Clostridioi...

STATEN ISLAND, N.Y. , Dec. 6, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics...

1 month ago - PRNewsWire

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2021 Results and Provides Business Update

STATEN ISLAND, N.Y., Nov. 12, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics...

2 months ago - PRNewsWire

Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI at the 9th International...

STATEN ISLAND, N.Y. , Nov. 8, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics...

2 months ago - PRNewsWire

Acurx Pharmaceuticals to Discuss 2021 Third Quarter Financial Results on November 15, 2021 Conference Call and Provid...

STATEN ISLAND, N.Y., Oct. 27, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics...

2 months ago - PRNewsWire

Acurx Presents Positive Ibezapolstat Microbiome Data from Its Phase 2a Trial at IDWeek

STATEN ISLAND, N.Y., Oct. 4, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics ...

3 months ago - PRNewsWire

Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021

WASHINGTON, Sept. 30, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations, today a...

3 months ago - PRNewsWire

Acurx Pharmaceuticals to Participate in the A.G.P. Biotech and Specialty Pharma Conference October 13, 2021

STATEN ISLAND, N.Y., Sept. 29, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotic...

3 months ago - PRNewsWire

Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI in a Scientific Poster P...

STATEN ISLAND, N.Y., Sept. 27, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotic...

3 months ago - PRNewsWire

CEO Spotlight: Acurx Pharmaceuticals in Focus with CEO David Luci Talking Potentially Transformative Phase 2b Trial, ...

Acurx Pharmaceutical's CEO tells Soulstring Media why he thinks 2021-22 can be a breakout year for his companyNew York, New York--(Newsfile Corp. - September 13, 2021) - Acurx Pharmaceuticals (NASDAQ: A...

4 months ago - Newsfile Corp

Acurx Pharmaceuticals to Join the Russell Microcap Index®

STATEN ISLAND, N.Y., Sept. 2, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics...

4 months ago - PRNewsWire

Acurx Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021

STATEN ISLAND, N.Y., Aug. 31, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics...

4 months ago - PRNewsWire

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2021 Results and Provides Business Update

STATEN ISLAND, N.Y., Aug. 16, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics...

5 months ago - PRNewsWire

Acurx Pharmaceuticals to Present at the Emerging Growth Conference on August 18, 2021

STATEN ISLAND, N.Y. , Aug. 12, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotic...

5 months ago - PRNewsWire

Acurx Pharmaceuticals Joins the Antimicrobials Working Group

WASHINGTON, Aug. 5, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (Acurx) to its coalition of companies with the ...

5 months ago - PRNewsWire

Health Holland Awards Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and A...

STATEN ISLAND, N.Y., Aug. 2, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq ACXP) ("Acurx" or the "Company") a clinical stage biopharmaceutical company developing a new class of antibiotics fo...

5 months ago - PRNewsWire

Acurx Pharmaceuticals to Discuss 2021 Second Quarter Financial Results on August 17, 2021 Conference Call and Provide...

STATEN ISLAND, N.Y., July 28, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics...

5 months ago - PRNewsWire

Acurx Announces Filing of Provisional Patent Application for Ibezapolstat to Treat CDI While Reducing Recurrence of I...

STATEN ISLAND, N.Y., July 7, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq ACXP) ("Acurx" or the "Company") a clinical stage biopharmaceutical company developing a new class of antibiotics fo...

6 months ago - PRNewsWire

Acurx Announces New Ibezapolstat Data on Anti-Recurrence Mechanisms in CDI at Prominent International Conference

STATEN ISLAND, N.Y. , July 1, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics ...

6 months ago - PRNewsWire

ACURX PHARMACEUTICALS, Inc. Announces Closing of INITIAL Public Offering OF common stock AND FULL EXERCISE OF UNDERWR...

STATEN ISLAND, N.Y., June 29, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) (the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for diffic...

6 months ago - PRNewsWire

Acurx Pharmaceuticals, Inc. announces pricing of $15 Million underwritten Initial public offering of common stock

STATEN ISLAND, N.Y., June 25, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) (the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for diffic...

6 months ago - PRNewsWire